Skip to content
Screener

Common Stock at other companies

Amgen logo
AmgenAMGN
2.8B0.0%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1K0.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
300M0.0%
Savara logo
SavaraSVRA
$204K+17.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$29K-3.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
200M0.0%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025; 54,771,041 and 54,237,750 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively5454
Additional paid-in capital685,542673,410
Accumulated other comprehensive income (expense)(123)530
Accumulated deficit(414,516)(334,223)
Total stockholders’ equity270,957339,771

Item 1. Financial Statements.

FAQ

What is Upstream Bio, Inc.'s common stock?
Upstream Bio, Inc. (UPB) reported common stock of $54K in Q2 2026.
How has Upstream Bio, Inc.'s common stock changed year-over-year?
Upstream Bio, Inc.'s common stock decreased by 0.0% year-over-year, from $54K to $54K.
What is the long-term trend for Upstream Bio, Inc.'s common stock?
Over 2 years (2023 to 2025), Upstream Bio, Inc.'s common stock has grown at a 324.3% compound annual growth rate (CAGR), from $3K to $54K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Upstream Bio, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude